1. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 66(4): 683- 691. 2017.
2. Hori M, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, et al. Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Japanese journal of clinical oncology. 2015;45(9):884-91.
3. Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda Aguilar E, Bardelli A, Benson A, Bodoky G, Ciardiello F, D'Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Köhne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Österlund P, Oyen WJG, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taïeb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology. 27(8): 1386-1422. 2016.
4. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 487(7407): 330-337. 2012.
5. Vogelstein B, Fearon ER, Kern SE, Hamilton SR, Preisinger AC, Nakamura Y, White R. Allelotype of colorectal carcinomas. Science (New York, NY). 244(4901): 207-211. 1989.
6. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 138(6): 2059-2072. 2010.
7. Leggett B, Whitehall V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology. 138(6): 2088-2100. 2010.
8. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 138(6): 2073-2087.e2073. 2010.
9. Ogino S, Nosho K, Kirkner GJ, Kawasaki1 T, Jeffrey AM, Massimo L, Edward LG, Charles SF. CpG islandmethylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in coloncancer. Gut. 58: 90―96. 2009
10. Lynch HT, Lynch PM, Lanspa SJ, Snyder CL, Lynch JF, Boland CR. Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clinical genetics. 76(1): 1-18. 2009.
11. Xiao Y, Freeman GJ. The microsatellite instable subset of colorectal cancer is a particularly good candidate for checkpoint blockade immunotherapy. Cancer discovery. 5(1): 16-18. 2015.
12. Lam AK, Chan SS, Leung M. Synchronous colorectal cancer: clinical, pathological and molecular implications. World journal of gastroenterology. 20(22): 6815-6820. 2014.
13. Nosho K, Kure S, Irahara N, Shima K, Baba Y, Spiegelman D, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology. 137(5): 1609-1620.e1601-1603. 2009.
14. Billroth T. Die allgemeine chirurgische pathologie und therapie: G. Reimer; 1889.
15. Warren S, Gates O. Multiple primary malignant tumors: survey of the literature and statistical study. Am J Cancer 16: 1358-1414. 1932.
16. Huang CS, Yang SH, Lin CC, Lan YT, Chang SC, Wang HS, Chen WS, Lin TC, Lin JK, Jiang JK. Synchronous and metachronous colorectal cancers: distinct disease entities or different disease courses? Hepato-gastroenterology. 62(138): 286-290. 2015.
17. Latournerie M, Jooste V, Cottet V, Lepage C, Faivre J, Bouvier AM. Epidemiology and prognosis of synchronous colorectal cancers. The British journal of surgery. 95(12): 1528-1533. 2008.
18. Yang J, Peng JY, Chen W. Synchronous colorectal cancers: a review of clinical features, diagnosis, treatment, and prognosis. Digestive surgery. 28(5-6): 379-385. 2011.
19. Mulder SA, Kranse R, Damhuis RA, de Wilt JH, Ouwendijk RJ, Kuipers EJ, van Leerdam ME. Prevalence and prognosis of synchronous colorectal cancer: a Dutch population-based study. Cancer epidemiology. 35(5): 442-447. 2011.
20. Ishida H, Yamaguchi T, Tanakaya K, Akagi K, Inoue Y, Kumamoto K, Shimodaira H, Sekine S, Tanaka T, Chino A, Tomita N, Nakajima T, Hasegawa H, Hinoi T, Hirasawa A, Miyakura Y, Murakami Y, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Sugihara K, Watanabe T, Japanese Society for Cancer of the C, Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer (Translated Version). Journal of the Anus, Rectum and Colon. 2(Suppl.I): S1-S51. 2018.
21. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Ruschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. Journal of the National Cancer Institute. 96(4): 261-268. 2004.
22. Lynch HT, de la Chapelle A. Genetic susceptibility to non-polyposis colorectal cancer. Journal of medical genetics. 36(11): 801-818. 1999.
23. Passman MA, Pommier RF, Vetto JT. Synchronous colon primaries have the same prognosis as solitary colon cancers. Diseases of the colon and rectum. 39(3): 329-334. 1996.
24. Oya M, Takahashi S, Okuyama T, Yamaguchi M, Ueda Y. Synchronous colorectal carcinoma: clinico-pathological features and prognosis. Japanese journal of clinical oncology. 33(1): 38-43. 2003.
25. Chen HS, Sheen-Chen SM. Synchronous and "early" metachronous colorectal adenocarcinoma: analysis of prognosis and current trends. Diseases of the colon and rectum. 43(8): 1093-1099. 2000.
26. Papadopoulos V, Michalopoulos A, Basdanis G, Papapolychroniadis K, Paramythiotis D, Fotiadis P, Berovalis P, Harlaftis N. Synchronous and metachronous colorectal carcinoma. Techniques in coloproctology. 8 Suppl 1: s97-s100. 2004.
27. Lam AK, Carmichael R, Gertraud Buettner P, Gopalan V, Ho YH, Siu S. Clinicopathological significance of synchronous carcinoma in colorectal cancer. American journal of surgery. 202(1): 39-44. 2011.
28. Bae JM, Cho NY, Kim TY, Kang GH. Clinicopathologic and molecular characteristics of synchronous colorectal cancers: heterogeneity of clinical outcome depending on microsatellite instability status of individual tumors. Diseases of the colon and rectum. 55(2): 181-190. 2012.
29. Hu H, Chang DT, Nikiforova MN, Kuan SF, Pai RK. Clinicopathologic features of synchronous colorectal carcinoma: A distinct subset arising from multiple sessile serrated adenomas and associated with high levels of microsatellite instability and favorable prognosis. The American journal of surgical pathology. 37(11): 1660-1670. 2013.
30. Malesci A, Basso G, Bianchi P, Fini L, Grizzi F, Celesti G, Di Caro G, Delconte G, Dattola F, Repici A, Roncalli M, Montorsi M, Laghi L. Molecular heterogeneity and prognostic implications of synchronous advanced colorectal neoplasia. British journal of cancer. 110(5): 1228-1235. 2014.
31. Kato T, Alonso S, Muto Y, Noda H, Miyakura Y, Suzuki K, Tsujinaka S, Saito M, Perucho M, Rikiyama T. Clinical characteristics of synchronous colorectal cancers in Japan. World journal of surgical oncology. 14(1): 272. 2016.
32. Gospodarowicz MK, Brierley JD, Wittekind C. TNM classification of malignant tumours: John Wiley & Sons; 2017.
33. Shibata J, Kawai K, Nishikawa T, Tanaka T, Tanaka J, Kiyomatsu T, Hata K, Nozawa H, Kazama S, Yamaguchi H, Ishihara S, Sunami E, Kitayama J, Sugihara K, Watanabe T. Prognostic Impact of Histologic Type in Curatively Resected Stage IV Colorectal Cancer: A Japanese Multicenter Retrospective Study. Ann Surg Oncol. 22: 621-629. 2015
34. Guinney J, Dienstmann R, Wang X, de Reynies A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa EMF, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L, Tejpar S. The consensus molecular subtypes of colorectal cancer. Nature medicine. 21(11): 1350-1356. 2015.
35. Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K, Beer A, Schwarz C, Loes IM, Smolle M, Kamphues C, He J, Pawlik TM, Kaczirek K, Poultsides G, Lonning PE, Cameron JL, Burkhart RA, Gerger A, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. JAMA surgery. 153(7): e180996. 2018.
36. Adloff M, Arnaud JP, Bergamaschi R, Schloegel M. Synchronous carcinoma of the colon and rectum: prognostic and therapeutic implications. American journal of surgery. 157(3): 299-302. 1989.
37. Jass JR, Do KA, Simms LA, Iino H, Wynter C, Pillay SP, Searle J, Radford-Smith G, Young J, Leggett B. Morphology of sporadic colorectal cancer with DNA replication errors. Gut. 42(5): 673-679. 1998.
38. Grady WM, Carethers JM. Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology. 135(4): 1079-1099. 2008.
39. Pedroni M, Tamassia MG, Percesepe A, Roncucci L, Benatti P, Lanza G, Jr., Gafa R, Di Gregorio C, Fante R, Losi L, Gallinari L, Scorcioni F, Vaccina F, Rossi G, Cesinaro AM, Ponz de Leon M. Microsatellite instability in multiple colorectal tumors. International journal of cancer Journal international du cancer. 81(1): 1-5. 1999.
40. Dykes SL, Qui H, Rothenberger DA, Garcia-Aguilar J. Evidence of a preferred molecular pathway in patients with synchronous colorectal cancer. Cancer. 98(1): 48-54. 2003.
41. Odin E, Wettergren Y, Nilsson S, Willen R, Carlsson G, Spears CP, Larsson L, Gustavsson B. Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research. 9(16 Pt 1): 6012-6019. 2003.
42. Giovannucci E, Ogino S. DNA methylation, field effects, and colorectal cancer. Journal of the National Cancer Institute. 97(18): 1317-1319. 2005.
43. Roth RM, Haraldsdottir S, Hampel H, Arnold CA, Frankel WL. Discordant Mismatch Repair Protein Immunoreactivity in Lynch Syndrome-Associated Neoplasms: A Recommendation for Screening Synchronous/Metachronous Neoplasms. American journal of clinical pathology. 146(1): 50-56. 2016.
44. Zauber P, Huang J, Sabbath-Solitare M, Marotta S. Similarities of molecular genetic changes in synchronous and metachronous colorectal cancers are limited and related to the cancers' proximities to each other. The Journal of molecular diagnostics : JMD. 15(5): 652-660. 2013.
45. Jesinghaus M, Pfarr N, Kloor M, Endris V, Tavernar L, Muckenhuber A, von Knebel Doeberitz M, Penzel R, Weichert W, Stenzinger A. Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies. Genes, chromosomes & cancer. 55(3): 268-277. 2016.
46. Giannini R, Lupi C, Loupakis F, Servadio A, Cremolini C, Sensi E, Chiarugi M, Antoniotti C, Basolo F, Falcone A, Fontanini G. and genotyping of synchronous colorectal carcinomas. Oncology letters. 7(5): 1532-1536. 2014.
47. Harada Y, Kazama S, Morikawa T, Murono K, Yasuda K, Otani K, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Hata K, Nozawa H, Yamaguchi H, Ishihara S, Watanabe T. Leucine-rich repeat-containing G protein-coupled receptor 5 and CD133 expression is associated with tumor progression and resistance to preoperative chemoradiotherapy in low rectal cancer. Oncology letters. 14(6): 7791-7798. 2017.
48. Reles A, Schmider A, Press MF, Schonborn I, Friedmann W, Huber-Schumacher S, Strohmeyer T, Lichtenegger W. Immunostaining of p53 protein in ovarian carcinoma: correlation with histopathological data and clinical outcome. Journal of cancer research and clinical oncology. 122(8): 489-494. 1996.
49. Eguchi K, Yao T, Konomoto T, Hayashi K, Fujishima M, Tsuneyoshi M. Discordance of p53 mutations of synchronous colorectal carcinomas. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 13(2): 131-139. 2000.
50. Morin PJ, Kinzler KW, Sparks AB. beta-Catenin Mutations: Insights into the APC Pathway and the Power of Genetics. Cancer research. 76(19): 5587-5589. 2016.
51. Jass JR, Biden KG, Cummings MC, Simms LA, Walsh M, Schoch E, Meltzer SJ, Wright C, Searle J, Young J, Leggett BA. Characterisation of a subtype of colorectal cancer combining features of the suppressor and mild mutator pathways. Journal of clinical pathology. 52(6): 455-460. 1999.
52. Nakano K, Yamamoto H, Fujiwara M, Koga Y, Tsuruta S, Ihara E, Oki E, Nakamura M, Ogawa Y, Oda Y. Clinicopathologic and Molecular Characteristics of Synchronous Colorectal Carcinoma With Mismatch Repair Deficiency. The American journal of surgical pathology. 42(2): 172-182. 2018.
53. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 33(1): 159-174. 1977.
54. Arakawa K, Hata K, Yamamoto Y, Nishikawa T, Tanaka T, Kiyomatsu T, Kawai K, Nozawa H, Yoshida M, Fukuhara H, Fujishiro M, Morikawa T, Yamasoba T, Koike K, Fukayama M, Watanabe T. Nine primary malignant neoplasms- involving the esophagus, stomach, colon, rectum, prostate, and external ear canal- without microsatellite instability: a case report. BMC cancer. 18(1): 24. 2018.
55. Malapelle U, Bellevicine C, Salatiello M, de Luca C, Rispo E, Riccio P, Sparano L, De Stefano A, Carlomagno C, Maiello FM, Vita G, Nappi O, Troncone G. Sanger sequencing in routine KRAS testing: a review of 1720 cases from a pathologist's perspective. Journal of clinical pathology. 65(10): 940-944. 2012.
56. Ahmed D, Eide PW, Eilertsen IA, Danielsen SA, Eknaes M, Hektoen M, Lind GE, Lothe RA. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis. 2: e71. 2013.
57. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA, Fodde R, Ranzani GN, Srivastava S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer research. 58(22): 5248- 5257. 1998.
58. Umetani N, Sasaki S, Watanabe T, Ishigami H, Ueda E, Nagawa H. Diagnostic primer sets for microsatellite instability optimized for a minimal amount of damaged DNA from colorectal tissue samples. Annals of surgical oncology. 7(4): 276-280. 2000.
59. Tanaka J, Watanabe T, Kanazawa T, Tada T, Kazama Y, Tanaka T, Nagawa H. Left-Sided microsatellite unstable colorectal cancers show less frequent methylation of hMLH1 and CpG island methylator phenotype than right-sided ones. Journal of surgical oncology. 96(7): 611-618. 2007.
60. Herman JG, Umar A, Polyak K, Graff JR, Ahuja N, Issa JP, Markowitz S, Willson JK, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogelstein B, Kunkel TA, Baylin SB. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 95(12): 6870-6875. 1998.
61. de Maat MF, Narita N, Benard A, Yoshimura T, Kuo C, Tollenaar RA, de Miranda NF, Turner RR, van de Velde CJ, Morreau H, Hoon DS. Development of sporadic microsatellite instability in colorectal tumors involves hypermethylation at methylated-in-tumor loci in adenoma. The American journal of pathology. 177(5): 2347-2356. 2010.
62. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proceedings of the National Academy of Sciences of the United States of America. 93(18): 9821- 9826. 1996.
63. Abe Y, Masuda H. Genetic alterations of sporadic colorectal cancer with microsatellite instability, especially characteristics of primary multiple colorectal cancers. Journal of surgical oncology. 74(4): 249-256. 2000.
64. Kamiyama H, Suzuki K, Maeda T, Koizumi K, Miyaki Y, Okada S, Kawamura YJ, Samuelsson JK, Alonso S, Konishi F, Perucho M. DNA demethylation in normal colon tissue predicts predisposition to multiple cancers. Oncogene. 31(48): 5029-5037. 2012.
65. Kumamoto K, Ishida H, Suzuki O, Tajima Y, Chika N, Kuwabara K, Ishibashi K, Saito K, Nagata K, Eguchi H, Tamaru J, Iwama T. Lower prevalence of Lynch syndrome in colorectal cancer patients in a Japanese hospital-based population. Surgery today. 46(6): 713-720. 2016.
66. Ishikubo T, Nishimura Y, Yamaguchi K, Khansuwan U, Arai Y, Kobayashi T, Ohkura Y, Hashiguchi Y, Tanaka Y, Akagi K. The clinical features of rectal cancers with high-frequency microsatellite instability (MSI-H) in Japanese males. Cancer letters. 216(1): 55-62. 2004.
67. Kadowaki S, Kakuta M, Takahashi S, Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K, Matsuo K, Muro K, Akagi K. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer. World journal of gastroenterology. 21(4): 1275-1283. 2015.
68. Balschun K, Haag J, Wenke AK, von Schonfels W, Schwarz NT, Rocken C. KRAS, NRAS, PIK3CA exon 20, and BRAF genotypes in synchronous and metachronous primary colorectal cancers diagnostic and therapeutic implications. The Journal of molecular diagnostics : JMD. 13(4): 436-445. 2011.
69. Sinicrope FA, Mahoney MR, Yoon HH, Smyrk TC, Thibodeau SN, Goldberg RM, Nelson GD, Sargent DJ, Alberts SR. Analysis of Molecular Markers by Anatomic Tumor Site in Stage III Colon Carcinomas from Adjuvant Chemotherapy Trial NCCTG N0147 (Alliance). Clinical cancer research : an official journal of the American Association for Cancer Research. 21(23): 5294-5304. 2015.
70. Mensenkamp AR, Vogelaar IP, van Zelst-Stams WA, Goossens M, Ouchene H, Hendriks-Cornelissen SJ, Kwint MP, Hoogerbrugge N, Nagtegaal ID, Ligtenberg MJ. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch- repair deficiency in Lynch syndrome-like tumors. Gastroenterology. 146(3): 643- 646.e648. 2014.
71. Benson AB, 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, Deming D, Engstrom PF, Enzinger PC, Fichera A, Grem JL, Grothey A, Hochster HS, Hoffe S, Hunt S, Kamel A, Kirilcuk N, Krishnamurthi S, Messersmith WA, Mulcahy MF, Murphy JD, Nurkin S, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Wu CS, Gregory KM, Freedman-Cass D. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : JNCCN. 15(3): 370-398. 2017.
72. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA, Jr. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. The New England journal of medicine. 372(26): 2509-2520. 2015.
73. Schiavon LHO, Tyng CJ, Travesso DJ, Rocha RD, Schiavon A, Bitencourt AGV. Computed tomography-guided percutaneous biopsy of abdominal lesions: indications, techniques, results, and complications. Radiol Bras. 51(3): 141-146. 2018
74. Koyanagi K, Bilchik AJ, Saha S, Turner RR, Wiese D, McCarter M, Shen P, Deacon L, Elashoff D, Hoon DS. Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(22): 7391-7396. 2008.
75. Modest DP, Ricard I, Heinemann V, Hegewisch-Becker S, Schmiegel W, Porschen R, Stintzing S, Graeven U, Arnold D, von Weikersthal LF, Giessen-Jung C, Stahler A, Schmoll HJ, Jung A, Kirchner T, Tannapfel A, Reinacher-Schick A. Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group. Annals of oncology : official journal of the European Society for Medical Oncology. 27(9): 1746-1753. 2016.
76. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska- Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. The New England journal of medicine. 369(11): 1023-1034. 2013.
77. Watanabe T, Kobunai T, Yamamoto Y, Matsuda K, Ishihara S, Nozawa K, Iinuma H, Shibuya H, Eshima K. Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer. Dis Colon Rectum 54(9): 1170-1178. 2011